O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued

• A.J. Kwon,
• G.J. Dore,
• J. Grebely,
• B. Hajarizadeh,
• R. Guy,
• E.B. Cunningham,
• C. Estes,
• H. Razavi,
• R.T. Gray

Affiliations

A.J. Kwon

Kirby Institute, UNSW Australia, Sydney, New South Wales, Australia

G.J. Dore

Kirby Institute, UNSW Australia, Sydney, New South Wales, Australia

J. Grebely

Kirby Institute, UNSW Australia, Sydney, New South Wales, Australia

B. Hajarizadeh

Kirby Institute, UNSW Australia, Sydney, New South Wales, Australia

R. Guy

Kirby Institute, UNSW Australia, Sydney, New South Wales, Australia

E.B. Cunningham

Kirby Institute, UNSW Australia, Sydney, New South Wales, Australia

C. Estes

Centre for Disease Analysis, Louisville, CO, USA

H. Razavi

Centre for Disease Analysis, Louisville, CO, USA

R.T. Gray

Kirby Institute, UNSW Australia, Sydney, New South Wales, Australia